National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 31702 [E8-12286]
Download as PDF
<![CDATA[
31702
Federal Register / Vol. 73, No. 107 / Tuesday, June 3, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
ebenthall on PRODPC60 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Immunogenetics of
Human Diabetes.
Date: July 16, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892.
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, HALT–PKD Clinical
Trials.
Date: July 22, 2008.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call)
Contact Person: D.G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Translational
Research.
Date: July 23, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD,
Scientific Review Officer, Review Branch,
VerDate Aug<31>2005
14:18 Jun 02, 2008
Jkt 214001
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: May 16, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–12286 Filed 6–2–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Geldanamycin Derivative and
Method of Treating Viral Infections
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the invention
embodied in U.S. Patent No. 6,890,917,
issued May 10, 2005, entitled
‘‘Geldanamycin Derivative and Method
of Treating Cancer Using Same’’ [E–
050–2000/0–US–15] and foreign
equivalents. The patent rights in these
inventions have been assigned to the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the use
of the manufacture, use, distribution
and sale of 17–DMAG, an analog of
geldanamycin, as a therapeutic to
inhibit the influenza virus, respiratory
syncytial virus (RSV) and dengue virus.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
August 4, 2008, will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Adaku Madu, J.D.,
Technology Licensing Specialist, Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
5560; Facsimile: (301) 402–0220; E-mail:
madua@mail.nih.gov.
This
technology relates to novel cytotoxic
compounds derived from 17aminoalkylamino-substituted
geldanamycin and pharmaceutical
compositions thereof. In particular, this
invention refers to 17-(dimehtylamino)
propylamino-geldanamycin, 17(dimethylamino) ethylaminogeldanamycin, and the hydrochloride
salt of 17-(dimethylamino) ethylaminogeldanamycin (DMAG and analogs).
These compounds are Hsp90 inhibitors.
Hsp90 inhibition downregulates B-Raf,
decreases cell proliferation and reduces
activation of the MEK/ERK pathways in
some cells. Hsp90 plays an essential
role in maintaining stability and activity
in its client proteins. Hsp90 inhibitors
interfere with diverse signaling
pathways by destabilizing and
attenuating activity of such proteins,
and thus exhibit antitumor activity.
Specifically, 17–DMAG shows
cytotoxicity against a number of human
colon and lung cell lines, specific
melanoma, renal and breast lines, and
potentially against various viral
infections. In addition, these
compounds appear to have favorable
pharmaceutical properties including
oral activity and improved watersolubility.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR Part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
SUPPLEMENTARY INFORMATION:
Dated: May 23, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–12289 Filed 6–2–08; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\03JNN1.SGM
03JNN1
]]>Agencies
[Federal Register Volume 73, Number 107 (Tuesday, June 3, 2008)]
[Notices]
[Page 31702]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-12286]
[[Page 31702]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Immunogenetics of Human
Diabetes.
Date: July 16, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892.
Contact Person: D.G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, HALT-PKD Clinical
Trials.
Date: July 22, 2008.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference Call)
Contact Person: D.G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Translational Research.
Date: July 23, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8898, barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: May 16, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-12286 Filed 6-2-08; 8:45 am]
BILLING CODE 4140-01-P
